Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program

NEXT STORY
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
PREV STORY
Broadway Gold Mining Ltd. Announces Proposed Acquisition of Mind Medicine, Inc. and Related Financing Transactions
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19

author_avatar
NASDAQ Market News

BioTelemetry Research and AMRA Raise the Standard for Medical Imaging in NASH/NAFLD Clinical Trials

MALVERN, Pa., Oct. 25, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless ...

author_avatar
NASDAQ Market News

Class Action Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

author_avatar
NASDAQ Market News